Daniel F. O'neill

Internal Medicine

730 Polk St Fl 4
San Francisco, CA 94109

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1 publications

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.

Journal: The Lancet. Neurology

Published: May 31, 2022

Showing 1-1 of 1

Last Updated: 09/26/2026